Polyphor

78 articles about Polyphor

• Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

  10/29/2020

  Polyphor AG announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic breast cancer.

• 

  BioSpace Global Roundup, Oct. 15

  10/15/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

  10/14/2020

  Polyphor AG, announced that it has received a new and second non-dilutive funding award from CARB-X, a global partnership led by Boston University dedicated to supporting the development of antibacterial products, to diagnose, prevent and treat drug-resistant infections.

• Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment

  9/29/2020

  Polyphor AG announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China.

• 

  BioSpace Global Roundup, Sept. 3

  9/3/2020

  Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.

• Polyphor announces progress of the Phase III immuno-oncology program with balixafortide. Renewed strategy in advancing antibiotics and oncology research and pipeline

  2/20/2020

  Polyphor AG, a research based clinical stage biopharmaceutical company, announces progress of the Phase III immuno-oncology program with balixafortide and a renewed strategy in advancing antibiotics and oncology research and pipeline.

• Polyphor announces changes to its Board of Directors

  11/20/2019

  Polyphor AG announced that Chairman of the Board Argeris "Jerry" Karabelas has resigned from the company for personal reasons, effective immediately.

• Polyphor to present at the H.C. Wainwright Global Investment Conference

  9/4/2019

  Polyphor AG announced that the company will present at the 21st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City.

• Polyphor announces financial results for the first half 2019 and realigns strategy

  9/4/2019

  Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.

• Polyphor to host a Key Opinion Leader Meeting in New York on novel approaches to the treatment of metastatic breast cancer

  8/20/2019

  Polyphor AG announced that it will host a Key Opinion Leader (KOL) breakfast meeting on novel approaches to the treatment of metastatic breast cancer on Friday, September 6, 2019 in New York City.

• Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options

  7/17/2019

  Polyphor announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous for hospital-acquired and ventilator-associated bacterial pneumonia which have been put on a voluntary temporary hold on May 9th, 2019.

• Polyphor appoints Frank Weber as new Chief Medical and Development Officer

  6/27/2019

  Polyphor AG announced the appointment of Frank Weber, M.D., as Chief Medical and Development Officer, effective September 1, 2019.

• Polyphor to present its antibiotic programs at the American Society of Microbiology (ASM) Microbe 2019 Conference

  6/20/2019

  Polyphor AG announced that it will provide an overview on its Outer Membrane Protein Targeting Antibiotics programs at the American Society of Microbiology Microbe 2019 Conference taking place in San Francisco, California, from June 20 to 24, 2019.

• Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer

  6/19/2019

  Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial.

• Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference

  6/7/2019

  Polyphor AG presented yesterday new data from pulmonary delivery of its lead antibacterial candidate of the novel Outer Membrane Protein Targeting Antibiotic class, murepavadin, at the 42nd European Cystic Fibrosis Conference in Liverpool, United Kingdom.

• Polyphor and the University of Zurich receive an award from Innosuisse to accelerate the development of a new class of antibiotics inhibiting the LPS transport pathway

  5/29/2019

  Polyphor and the University of Zurich receive an award from Innosuisse to accelerate the development of a new class of antibiotics inhibiting the LPS transport pathway

• Polyphor Announces Presentation of New Survival Data on Balixafortide at the ASCO Annual Meeting 2019

  5/20/2019

  Polyphor AG announced that it will present new clinical data on survival outcomes of the Phase I trial of balixafortide, our lead immuno-oncology candidate, in combination with eribulin in HER2 negative metastatic breast cancer at the 2019 American Society of Clinical Oncology Annual Meeting being held in Chicago, May 31 - June 4, 2019.

• 

  Clinical Catch-up from Last Week: May 13-17

  5/20/2019

  Here's a roundup of some of the top clinical trial news from the previous week.
• 

  Polyphor Shares Plunge After it Halts Enrollment in Two Pneumonia Trials Due to Safety Concerns

  5/13/2019

  The company said that its lead product was creating greater-than anticipated kidney injuries in trial patients.

• Polyphor Temporarily Halts Enrollment in the Phase III Studies of Murepavadin for the Treatment of Patients With Nosocomial Pneumonia

  5/9/2019

  Polyphor announced the decision to temporarily halt enrollment for the pivotal Phase III trials PRISM-MDR and PRISM-UDR evaluating murepavadin in patients with nosocomial pneumonia due to higher than expected acute kidney injury incidences in the murepavadin arm of the PRISM-MDR trial.